Literature DB >> 16537547

Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference.

Claudia Weber1, Fernanda Mello de Queiroz, Bryan R Downie, Arnt Suckow, Walter Stühmer, Luis A Pardo.   

Abstract

EagI potassium channels are natively expressed in the mammalian brain as well as in many cancer cell lines and tumor tissues. The role of EagI in malignant transformation has been suggested by several experiments, but the lack of specific EagI inhibitors has made it difficult to examine the influence of the channel on oncogenesis and its potential as a therapeutic target. We have used short interfering RNA to test the effects of EagI reduction on the behavior of tumor cells in vitro. By generating and optimizing an EagI-specific short interfering RNA system, we were able to study the effects of EagI depletion on several cancer cell lines that endogenously express this protein. We show here that our short interfering RNA sequences act specifically on EagI, reproducibly induce a significant decrease in the proliferation of tumor cell lines, and do not trigger any observable nonspecific responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537547     DOI: 10.1074/jbc.M600883200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Cell cycle-dependent expression of potassium channels and cell proliferation in rat mesenchymal stem cells from bone marrow.

Authors:  X L Deng; C P Lau; K Lai; K F Cheung; G K Lau; G R Li
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

2.  Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation.

Authors:  Eva Herrero-Herranz; Luis A Pardo; Gertrude Bunt; Ralf Gold; Walter Stühmer; Ralf A Linker
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

3.  The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors.

Authors:  J W Roy; E A Cowley; J Blay; P Linsdell
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

Review 4.  The life and death of breast cancer cells: proposing a role for the effects of phytoestrogens on potassium channels.

Authors:  Joanne L Wallace; Iain F Gow; Mary Warnock
Journal:  J Membr Biol       Date:  2011-07-05       Impact factor: 1.843

5.  Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC.

Authors:  María de Guadalupe Chávez-López; Julio Isael Pérez-Carreón; Violeta Zuñiga-García; José Díaz-Chávez; Luis A Herrera; Claudia Haydee Caro-Sánchez; Isabel Acuña-Macías; Patricio Gariglio; Elizabeth Hernández-Gallegos; Andrea Jazmín Chiliquinga; Javier Camacho
Journal:  Tumour Biol       Date:  2015-03-18

6.  Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines.

Authors:  Xiang-Wu Ding; He-sheng Luo; Xiong Jin; Juan-juan Yan; Yao-wei Ai
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Identifying regulators for EAG1 channels with a novel electrophysiology and tryptophan fluorescence based screen.

Authors:  Tinatin I Brelidze; Anne E Carlson; Douglas R Davies; Lance J Stewart; William N Zagotta
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

Review 8.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

9.  Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines.

Authors:  Xiang-Wu Ding; Juan-Juan Yan; Ping An; Peng Lü; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.

Authors:  Jasmin R Agarwal; Frank Griesinger; Walter Stühmer; Luis A Pardo
Journal:  Mol Cancer       Date:  2010-01-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.